Atrium Therapeutics - Latest News and Information
Atrium Therapeutics is a biotechnology company focused on precision RNA medicines for the heart. It has developed an RNA delivery platform designed to deliver therapies directly to heart muscle, aiming to address rare cardiomyopathies with high unmet medical need. The company is pursuing lead candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for phospholamban (PLN) cardiomyopathy, with plans to file an IND in 2026. Based in the United States, Atrium emphasizes translating RNA-based precision cardiology into tangible treatments for patients with genetic heart diseases.
No recent news for this company.
